Your Patients Need Octreotide — Here's How to Help Them Get It

When a patient with acromegaly or carcinoid syndrome calls to say their pharmacy can't fill their Octreotide prescription, the clock starts ticking. These patients can't afford treatment gaps — uncontrolled growth hormone levels and carcinoid crises are real clinical risks.

As a provider, you're in a unique position to help. You have relationships with specialty pharmacies, access to manufacturer resources, and the clinical knowledge to navigate formulation changes. This guide gives you a practical, step-by-step approach to helping your patients find Octreotide in stock.

Current Availability Snapshot

Understanding what's available helps you guide your patients effectively:

What's generally available:

• Generic Octreotide immediate-release injection (subcutaneous/IV) from Avet, Fresenius Kabi, and Hikma
• Sandostatin LAR Depot (Novartis brand) — generally available, may be subject to allocation
• Mycapssa oral capsules (for acromegaly maintenance patients only)

What's intermittently available:

• Teva generic Octreotide LAR — production ramping up; some strengths on back order
• Sagent generic immediate-release injection — manufacturing delays

What's discontinued:

• Bynfezia Pen (Sun Pharma) — discontinued in 2021

For real-time pharmacy-level data, use Medfinder for Providers.

Why Patients Can't Find Octreotide

Before jumping to solutions, it's helpful to understand why your patients are hitting walls:

Specialty Distribution Model

Octreotide LAR is distributed exclusively through specialty pharmacies. Most patients can't simply walk into their local pharmacy and pick it up. This limits access points and creates bottlenecks when supply is tight.

Manufacturing Complexity

The LAR microsphere formulation requires specialized production facilities. Even Teva — a major generics manufacturer — has struggled to reach full production capacity since their October 2024 approval. Quality deviations at any stage can sideline production for months.

Insurance Barriers

Many patients face prior authorization requirements, step therapy protocols, and specialty pharmacy mandates that slow down the process of getting Octreotide — especially when switching formulations or manufacturers due to availability.

Information Gaps

Patients often don't know they have options. They may not be aware of all available formulations, generic alternatives, or tools like Medfinder that can help them locate supply.

What Providers Can Do: 5 Steps

Step 1: Identify All Available Formulations

When a specific Octreotide product is unavailable, systematically check all alternatives:

1. Generic immediate-release injection (multiple manufacturers — most widely available)
2. Sandostatin LAR Depot (Novartis brand LAR)
3. Teva generic Octreotide LAR
4. Mycapssa oral capsules (if the patient has acromegaly and has previously tolerated injectable SSA)

Prescribing a specific manufacturer's product when one is available while another is not can make the difference for your patient.

Step 2: Use Real-Time Availability Tools

Medfinder for Providers allows you to search pharmacy inventory data to find where Octreotide is in stock. This eliminates the guesswork and phone-tag that slows down the process for patients and staff alike.

You can also check the ASHP Drug Shortage Database for manufacturer-level updates on expected resolution dates and available alternatives.

Step 3: Leverage Your Specialty Pharmacy Relationships

Your practice likely has established relationships with specialty pharmacies for oncology and endocrinology medications. Use these relationships to:

• Request priority allocation for your patients
• Get early notification when new shipments arrive
• Set up automatic reorders for patients on recurring LAR injections
• Explore whether the pharmacy can source from alternative distributors

If you administer LAR injections in-office, your buy-and-bill supply channel may have better access than retail specialty pharmacies. Check with your distributors directly.

Step 4: Expedite Insurance Authorizations

Shortage-related switches often trigger new prior authorization requirements. Streamline this process by:

• Documenting the shortage as the clinical rationale for the switch
• Referencing ASHP or FDA shortage notifications in your authorization request
• Requesting expedited or urgent review from the payer
• Having your staff prepare standard shortage-related switch documentation that can be used across patients

Most payers will accommodate shortage-driven formulary exceptions when properly documented.

Step 5: Proactively Communicate with Patients

Don't wait for patients to call in a panic. If you know Octreotide supply is tight:

• Contact affected patients proactively to discuss contingency plans
• Educate patients about Medfinder and other self-service tools
• Provide written instructions for what to do if they can't fill their prescription
• Set expectations about potential formulation or manufacturer switches

Therapeutic Alternatives

When Octreotide is completely unavailable, the following alternatives should be considered:

• Lanreotide (Somatuline Depot): First-line alternative for acromegaly and GEP-NETs. Deep subcutaneous injection every 4 weeks. Different manufacturer (Ipsen) with an independent supply chain.
• Pasireotide LAR (Signifor LAR): For acromegaly patients inadequately controlled on first-generation SSAs. Higher hyperglycemia risk — requires glucose monitoring.
• Pegvisomant (Somavert): Growth hormone receptor antagonist for acromegaly. Different mechanism of action. Daily subcutaneous injection.
• Telotristat Ethyl (Xermelo): Add-on oral therapy for carcinoid syndrome diarrhea. Not a standalone SSA replacement.

For detailed clinical comparisons, see Alternatives to Octreotide.

Workflow Tips for Your Practice

Integrate shortage management into your practice workflow:

• Maintain a shortage tracker: Designate a staff member to monitor ASHP and FDA shortage databases weekly for Octreotide updates.
• Create bridging order sets: Develop standardized order sets for transitioning patients from LAR to immediate-release Octreotide, including dose conversion guidelines and monitoring parameters.
• Build a pharmacy contact list: Maintain an up-to-date list of specialty pharmacies with contact information and typical Octreotide stock levels.
• Document shortage encounters: Track shortage-related treatment modifications in the medical record for continuity and payer documentation.
• Schedule proactive refill checks: For patients on LAR injections, build refill verification into the scheduling workflow 3 weeks before each injection date.

Final Thoughts

Drug shortages are a frustrating reality, but providers who plan ahead and use the right tools can minimize the impact on patient care. Medfinder for Providers gives you real-time pharmacy availability data, and the strategies in this guide can help you keep your patients on therapy even when supply is tight.

For more provider-focused resources, see our articles on the Octreotide shortage overview for providers and how to help patients save money on Octreotide.